<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Med (Lausanne)</journal-id><journal-id journal-id-type="iso-abbrev">Front Med (Lausanne)</journal-id><journal-id journal-id-type="publisher-id">Front. Med.</journal-id><journal-title-group><journal-title>Frontiers in Medicine</journal-title></journal-title-group><issn pub-type="epub">2296-858X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7419580</article-id><article-id pub-id-type="doi">10.3389/fmed.2020.00420</article-id><article-categories><subj-group subj-group-type="heading"><subject>Medicine</subject><subj-group><subject>Mini Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Secondary Bacterial Infections in Patients With Viral Pneumonia</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Manohar</surname><given-names>Prasanth</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/549745/overview"/></contrib><contrib contrib-type="author"><name><surname>Loh</surname><given-names>Belinda</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/975929/overview"/></contrib><contrib contrib-type="author"><name><surname>Nachimuthu</surname><given-names>Ramesh</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/702394/overview"/></contrib><contrib contrib-type="author"><name><surname>Hua</surname><given-names>Xiaoting</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/277921/overview"/></contrib><contrib contrib-type="author"><name><surname>Welburn</surname><given-names>Susan C.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/384268/overview"/></contrib><contrib contrib-type="author"><name><surname>Leptihn</surname><given-names>Sebastian</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/181976/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Zhejiang University-University of Edinburgh (ZJU-UoE) Institute, Zhejiang University</institution>, <addr-line>Haining</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>School of Medicine, The Second Affiliated Hospital Zhejiang University (SAHZU)</institution>, <addr-line>Hangzhou</addr-line>, <country>China</country></aff><aff id="aff3"><sup>3</sup><institution>Antibiotic Resistance and Phage Therapy Laboratory, School of Bio Sciences and Technology, Vellore Institute of Technology (VIT)</institution>, <addr-line>Vellore</addr-line>, <country>India</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Infectious Diseases, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine</institution>, <addr-line>Hangzhou</addr-line>, <country>China</country></aff><aff id="aff5"><sup>5</sup><institution>Key Laboratory of Microbial Technology and Bioinformatics of Zhejiang Province</institution>, <addr-line>Hangzhou</addr-line>, <country>China</country></aff><aff id="aff6"><sup>6</sup><institution>Infection Medicine, Biomedical Sciences, Edinburgh Medical School, College of Medicine and Veterinary Medicine, The University of Edinburgh</institution>, <addr-line>Edinburgh</addr-line>, <country>United Kingdom</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Rodolfo Garc&#x000ed;a-Contreras, National Autonomous University of Mexico, Mexico</p></fn><fn fn-type="edited-by"><p>Reviewed by: Michael Bachman, University of Michigan, United States; Srijon Kaushik Banerjee, University of Arkansas for Medical Sciences, United States; Yael Gonz&#x000e1;lez Tinoco, Center for Scientific Research and Higher Education in Ensenada (CICESE), Mexico</p></fn><corresp id="c001">*Correspondence: Sebastian Leptihn <email>Leptihn@intl.zju.edu.cn</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Medicine</p></fn></author-notes><pub-date pub-type="epub"><day>05</day><month>8</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>05</day><month>8</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>7</volume><elocation-id>420</elocation-id><history><date date-type="received"><day>15</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>30</day><month>6</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Manohar, Loh, Nachimuthu, Hua, Welburn and Leptihn.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Manohar, Loh, Nachimuthu, Hua, Welburn and Leptihn</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Pulmonary diseases of viral origin are often followed by the manifestation of secondary infections, leading to further clinical complications and negative disease outcomes. Thus, research on secondary infections is essential. Here, we review clinical data of secondary bacterial infections developed after the onset of pulmonary viral infections. We review the most recent clinical data and current knowledge of secondary bacterial infections and their treatment in SARS-CoV-2 positive patients; case reports from SARS-CoV, MERS-CoV, SARS-CoV2 and the best-studied respiratory virus, influenza, are described. We outline treatments used or prophylactic measures employed for secondary bacterial infections. This evaluation includes recent clinical reports of pulmonary viral infections, including those by COVID-19, that reference secondary infections. Where data was provided for COVID-19 patients, a mortality rate of 15.2% due to secondary bacterial infections was observed for patients with pneumonia (41 of 268). Most clinicians treated patients with SARS-CoV-2 infections with prophylactic antibiotics (63.7%, <italic>n</italic> = 1,901), compared to 73.5% (<italic>n</italic> = 3,072) in all clinical reports of viral pneumonia included in this review. For all cases of viral pneumonia, a mortality rate of 10.9% due to secondary infections was observed (53 of 482). Most commonly, quinolones, cephalosporins and macrolides were administered, but also the glycopeptide vancomycin. Several bacterial pathogens appear to be prevalent as causative agents of secondary infections, including antibiotic-resistant strains of <italic>Staphylococcus aureus</italic> and <italic>Klebsiella pneumoniae</italic>.</p></abstract><kwd-group><kwd>secondary bacterial infection</kwd><kwd>pulmonary viruses</kwd><kwd>viral pneumonia</kwd><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>influenza</kwd><kwd>SARS</kwd><kwd>antibiotic resistance</kwd></kwd-group><counts><fig-count count="1"/><table-count count="0"/><equation-count count="0"/><ref-count count="85"/><page-count count="8"/><word-count count="6414"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Viruses causing respiratory tract infections have been the cause of high morbidities and mortality rates worldwide, often in a seasonal manner for decades (<xref rid="B1" ref-type="bibr">1</xref>). In the last 20 years, the world has experienced six major outbreaks of infectious agents (SARS-CoV: 2002-2004; H1N1 Influenza: 2009&#x02013;2010; MERS-CoV: 2012&#x02013;2020; Ebola virus: 2013&#x02013;2016; Zika virus: 2015&#x02013;2016; SARS-CoV-2: 2019-present), infection with four of which (SARS-CoV, H1N1 Influenza, MERS-CoV, SARS-CoV-2) result in respiratory tract infections. During the emergency of a viral disease, attention is initially focussed on clinical management of the primary infection, but it is imperative to consider secondary bacterial infections that develop in patients during or following initial infection. In addition, co-infections - the simultaneous infection with a second pathogen of viral or bacterial origin- can also occur and ultimately result in the same outcome: The patient suffers from complications caused by two different pathogens (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). One major complication of viral infections, especially pulmonary viruses, is colonization of the viral affected organs by bacteria which is associated with high morbidity and mortality rates (<xref ref-type="fig" rid="F1">Figure 1A</xref>), following a weakened immune response and/or opportunistic and accessible routes of entry for bacterial pathogen(s) (<xref rid="B4" ref-type="bibr">4</xref>). While secondary bacterial infections or superinfections are largely a consequence of immune susceptibility caused by the primary viral infection, co-infections are multiple infections (viral/bacterial/yeast) that occur simultaneously. Co-infections, secondary infections or &#x0201c;superinfections&#x0201d; are common during viral pandemics. The 1918 Spanish Flu pandemic saw around 50 million deaths ascribed to bacterial co-infections and during the 2009 H1N1 Influenza pandemic up to 34% of all deaths were a result of bacterial co-infections (<xref rid="B5" ref-type="bibr">5</xref>). These complications are often neglected in the clinical record (<xref ref-type="fig" rid="F1">Figure 1B</xref>) (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>(A)</bold> Possible disease progression after infection with a respiratory virus. <bold>(B)</bold> Overview of case reports of all respiratory virus infection data reviewed in this study, including rate of secondary bacterial infections, antibiotic use and pathogenic bacteria identified.</p></caption><graphic xlink:href="fmed-07-00420-g0001"/></fig><p>While the precise mechanism for susceptibility to secondary infections is poorly understood, it is likely that virus-mediated immunosuppression of the host innate immune enables opportunistic bacteria to colonize the host as it was shown for <italic>Streptococcus</italic> (<xref rid="B8" ref-type="bibr">8</xref>). Most studies on host-pathogen interactions focus on a single-pathogen, one-host model although mammalian hosts are simultaneously exposed to multiple (opportunistic) pathogens (<xref rid="B9" ref-type="bibr">9</xref>). The immune response to one pathogen may alter the immunity to other infectious agent(s), resulting in increased prevalence of viral-induced secondary bacterial infections (<xref rid="B10" ref-type="bibr">10</xref>). Mammalian cells are more susceptible to bacterial attachment and colonization when infected by a virus (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>); infection with respiratory syncytial virus (RSV), rhinovirus and influenza virus (all of which damage the mucosal layer), lead to bacterial adherence of <italic>Streptococcus pneumoniae, Pseudomonas aeruginosa</italic>, and <italic>Haemophilus influenzae</italic>, and biofilm formation on the linings of the airways (<xref rid="B13" ref-type="bibr">13</xref>).</p><p>Common bacteria isolated during secondary infections include <italic>Staphylococcus aureus, S. pneumoniae, Neisseria meningitides, H. influenzae, Klebsiella pneumoniae</italic> and members of the <italic>Proteus, Enterobacter</italic> and <italic>Citrobacter</italic> spp. (<xref rid="B14" ref-type="bibr">14</xref>). During active viral infections, the route of infection, proximity of infection as well as virulence factors varies between bacterial strains resulting in different outcomes. Effective treatment of both the viral and the secondary bacterial infection(s) is of critical importance. Antiviral treatments deployed initially do not treat secondary bacterial infections (<xref rid="B15" ref-type="bibr">15</xref>). The preferred treatment for bacterial infections is generally broad-spectrum antibiotics, but this can result in undesirable side effects that have a negative impact on the normal microflora of the host (<xref rid="B16" ref-type="bibr">16</xref>&#x02013;<xref rid="B18" ref-type="bibr">18</xref>). Susceptible individuals within a population can be protected from risk of some common bacterial pathogens that are also capable to cause secondary infections, for example pneumonia, if vaccines are available; furthermore, the immune system is often capable of fighting bacterial infections alone, while during a virus-bacterial infection, the complex immune responses might be inapt to eliminate bacterial-induced disease complications (<xref rid="B19" ref-type="bibr">19</xref>). To reduce severe disease progression or lethal outcomes, alternative ways to alleviate complications due to secondary bacterial infections and to eliminate bacterial pathogens while preserving host immunity might be necessary.</p><p>Secondary infections can also be acquired from the patient's environment i.e., hospital-acquired or nosocomial infections. Nosocomial pathogens are often resistant to a wide range of antibiotics; a result of increased use of antibiotics and decades of over- and misuse resulting in selection for multi-drug resistant pathogens (MDR pathogens) (<xref rid="B20" ref-type="bibr">20</xref>). MDR is a global problem with &#x0003e;50,000 people per year infected, of which in ~25% of the cases no effective antibiotic is available (<xref rid="B21" ref-type="bibr">21</xref>) as many major pharmaceutical stakeholders have discontinued their search for new chemical antimicrobials (<xref rid="B22" ref-type="bibr">22</xref>). Antibiotic resistant organisms include Methicillin-resistant <italic>S. aureus</italic> (MRSA), Drug-resistant <italic>Streptococcus</italic>, Vancomycin-resistant <italic>Enterococci</italic> (VRE), drug-resistant <italic>Mycobacterium</italic>, Carbapenem-resistant <italic>Enterobacteriaceae</italic> (CRE), Colistin-resistant <italic>Klebsiella</italic>, Carbapenem-resistant <italic>Pseudomonas aeruginosa</italic>, and Carbapenem-resistant <italic>Acinetobacter baumannii</italic> (<xref rid="B20" ref-type="bibr">20</xref>). If a patient with a viral infection is unfortunate to become infected by MDR bacteria, no standard treatment is currently available. In one COVID-19 cohort study, described in more detail below; almost 50% (10 of 21) patients developed secondary bacterial infections in the lung caused by <italic>Klebsiella pneumoniae, Staphylococcus, Acinetobacter baumannii</italic>, and <italic>E. coli</italic>, ultimately leading to their death, despite receiving prophylactic antibiotic therapy (<xref rid="B23" ref-type="bibr">23</xref>).</p><p>This evaluation of all the COVID-19 reports available that reference secondary infections showed that most clinicians prescribed meropenem and linezolid to children with a rate of prophylactic treatment between 19.4 and 100.0% (<xref rid="B24" ref-type="bibr">24</xref>). In adults mainly quinolones, cephalosporins and macrolides were used for treatment with rates of prophylaxis between 13.2 and 100.0%. In most cases, etiological evidence was not used for therapeutic use of antibiotics.</p><p>In this study, we have assimilated the most recent clinical data on bacterial secondary infections associated with pneumonias, caused by pulmonary viruses, including for SARS-CoV-2. We outline treatments used or prophylactic measures employed for secondary bacterial infections. This review focuses on secondary bacterial infections that occur in the respiratory tissue of patients suffering from a viral infection, as most lung infections by secondary bacterial pathogens remain localized in the respiratory tract, while a small percentage leads to infections that spread systematically.</p></sec><sec id="s2"><title>COVID-19 Related Secondary Bacterial Infections and Treatment</title><p>SARS-CoV-2 is an enveloped, positive-sense, single-stranded RNA virus, belonging to the family Coronaviridae. The virus emerged in 2019 and is responsible for respiratory illnesses Coronavirus Disease 2019 (COVID-19) that results in respiratory tract infections and causes severe lung damage in most fatal cases. SARS-CoV-2 has overwhelmed health systems, with numbers of those infected with COVID-19 requiring hospitalization and critical care.</p><p>Early stages of SARS-CoV-2 infection typically include symptoms of mild fever and shortness of breath (<xref rid="B25" ref-type="bibr">25</xref>). As the virus replicates in the respiratory tract, the symptoms worsen and once the virus reaches and begins infecting the alveoli, the host responds by generating inflammatory factors in alveolar tissues that may result in pneumonia. In almost all severe cases, SARS-CoV-2 infection results in pneumonia and the inflamed fluid-filled alveolar tissue now is an ideal habitat for bacterial growth for pathogens including <italic>P. aeruginosa</italic> and <italic>S. aureus</italic>. The causative agent resulting in a severe disease progression may be bacteria, virus or fungi (<xref rid="B26" ref-type="bibr">26</xref>).</p><p>The presence of secondary bacterial infections in those infected with SARS-CoV-2 complicates treatment (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>). An overview of all COVID-19 case studies, available as <xref ref-type="supplementary-material" rid="SM3">Supplementary Information</xref>, where we have analyzed 15 case studies reporting SARS-CoV-2 infection (Supplemental Data Sheet 1). In particular for data obtained from clinical observations in China, COVID-19 patients are most commonly treated with antibiotics (azithromycin, moxifloxacin, ceftriaxone, vancomycin, cefepime) to reduce the risk of nosocomial infections, a prophylactic strategy. Should a bacterial infection occur despite the prophylactic use of antibiotics, caused by bacteria that are resistant to one or more drugs, different combinations of the same drugs are being used for the treatment, as a therapeutic strategy. Both strategies, the prophylactic and the therapeutic use of antibiotics, deploy the same types and dosage of drugs: however the prophylactic use of antibiotics is not recommended by most health institutions and governments around the globe, due to the observed increase in antibiotic resistance rates, which correlate with the overuse (and misuse) of antibiotics (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>). However, the risk of superinfection with MDR bacteria poses additional challenges for the treatment of severely sick COVID-19 patients in intensive care units (ICU).</p></sec><sec id="s3"><title>Case Reports of Antibacterial Therapy in COVID-19 Patients</title><p>Fifteen clinical reports, for which data for secondary infections were available, mainly from hospitals in China, were examined to provide information of the occurrence, treatment of or prophylactic measures for bacterial secondary infections during the course of COVID-19 infections (<xref ref-type="supplementary-material" rid="SM2">Supplementary File</xref>). A total of 3,133 COVID-19 patient cases were detailed in the 15 reports (<xref rid="B25" ref-type="bibr">25</xref>&#x02013;<xref rid="B39" ref-type="bibr">39</xref>). Prophylactic antibiotic therapy was given to 1,901 of the 2,983 patients (63.7%). We excluded one study (patient <italic>n</italic> = 150), as they did not report details on the antibiotic therapy (<xref rid="B31" ref-type="bibr">31</xref>) and 5/14 studies did not report the type of antibiotics used. The most commonly used antibiotics were moxifloxacin (<italic>n</italic> = 452, 39.2%) and azithromycin (<italic>n</italic> = 294, 30.7%). Others include ceftriaxone, vancomycin, cefepime, cephalosporins, quinolones, carbapenems, tigecycline, doxycycline, and cefoperazone. In total, 10 studies reported secondary bacterial infections, with 273 of the 997 patients (27.3%) being infected. Again, we excluded 5 studies (patients <italic>n</italic> = 2,136), which did not report any information on any clinical complications other than caused by the SARS-CoV-2 virus (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B37" ref-type="bibr">37</xref>). The most common bacterial infections were caused by the Gram-positive pathogen <italic>Staphylococcus aureus</italic> or by strains of the Gram-negative bacterium <italic>Klebsiella pneumoniae</italic>. Five studies reported infections that were confirmed by tests in a microbiology laboratory, which identified MRSA, MSSA, <italic>Serratia, Acinetobacter, Pseudomonas, E. coli, H. influenza</italic>, and <italic>E. cloacae</italic> (patients <italic>n</italic> = 16) (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B38" ref-type="bibr">38</xref>). Three studies reported therapeutic antibiotic treatment in 92 of 146 patients (63%), which were administered as secondary bacterial infections were observed (<xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B39" ref-type="bibr">39</xref>). Four studies reported complications with fatal outcome due to bacterial infections that included 41 of 268 patients (15.2%) (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B39" ref-type="bibr">39</xref>). An overview of the studies can be found in <xref ref-type="supplementary-material" rid="SM1">Supplementary Figure 1</xref>, which also provides the information on percentages of antibiotic use and types of antibiotic compounds, among others.</p><p>These clinical reports provide insights into the complications and challenges faced in treating SARS-CoV-2 infected patients. Patients with pneumonia caused by other respiratory viruses or SARS-CoV-2 pneumonia patients were often prophylactically treated with broad-spectrum antibiotics, in an attempt to reduce the risk of bacterial superinfections. Complications were observed in patients that were not treated with antibiotics. Antibiotic-resistant infections, in particular, nosocomial - hospital-acquired - infections were common for more than one third of ICU patients, posing a threat to disease progression, often resulting in the death of the affected individual (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B40" ref-type="bibr">40</xref>).</p></sec><sec id="s4"><title>SARS-related Secondary Bacterial Infections and Treatment</title><p>Severe Acute Respiratory Syndrome-related Coronavirus (SARS) Co-V, was first report in Guangdong Province, China in November 2002. At its initial outbreak (until August 2003), 8,096 probable cases were reported with an ~10% fatality rate (<xref rid="B41" ref-type="bibr">41</xref>). Further sporadic cases were reported in November 2003 through April 2004 (<xref rid="B42" ref-type="bibr">42</xref>). The case studies showed the occurrence of bacterial co-infections in the large number of patients. These include infections by MRSA, <italic>Klebsiella</italic> spp., <italic>P. aeruginosa</italic> and <italic>Streptococcus</italic> (<xref rid="B43" ref-type="bibr">43</xref>). The large multinucleated cells observed in the lungs of the SARS patients may be due to the underlining bacterial infections (<xref rid="B43" ref-type="bibr">43</xref>). The use of broad-spectrum antibiotics to cover the secondary bacterial infections is one of the supportive cares during SARS outbreak (<xref rid="B44" ref-type="bibr">44</xref>) (<xref ref-type="supplementary-material" rid="SM2">Supplementary File</xref>). The case studies (<italic>n</italic> = 7) reported the disease progression of a total of 534 SARS-CoV patients (<xref rid="B45" ref-type="bibr">45</xref>&#x02013;<xref rid="B51" ref-type="bibr">51</xref>) (<xref ref-type="supplementary-material" rid="SM2">Supplementary File</xref>). Details about prophylactic antibiotic therapy was reported in five studies (patients <italic>n</italic> = 385) and 100% patients were treated with prophylactic antibiotic therapy (<xref rid="B48" ref-type="bibr">48</xref>, <xref rid="B50" ref-type="bibr">50</xref>&#x02013;<xref rid="B53" ref-type="bibr">53</xref>). The antibiotics used for prophylactic treatment were levofloxacin, clarithromycin, amoxicillin-clavulanic acid, piperacillin-tazobactum, maxipime, azithromycin, amoxicillin-clavulanate, cefoperazone/sulbactam, quinolone plus azithromycin, levofloxacin, moxifloxacin, and ceftriaxone plus azithromycin, and most commonly azithromycin (<italic>n</italic> = 206, 74.6%). Of the four studies that reported secondary bacterial infections, 35 of 306 patients (11.4%) became infected. The pathogens that caused the infections included <italic>P. aeruginosa</italic>, MRSA, <italic>S. pneumoniae, K. pneumoniae, Enterococci, Acinetobacter baumannii, Enterobacter, H. influenza, S. maltophilia</italic>, and <italic>Serratia</italic> (<xref rid="B45" ref-type="bibr">45</xref>, <xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B51" ref-type="bibr">51</xref>). Despite the deployment of prophylactic antibiotics, the use of therapeutic antibiotics was reported in three studies, administering amoxicillin-clavulanate, clarithromycin, azithromycin, levofloxacin, moxifloxacin and ceftriaxone plus azithromycin (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B49" ref-type="bibr">49</xref>, <xref rid="B51" ref-type="bibr">51</xref>). In total, 12 patients out of 23 (52%, described in two studies who provided the respective information) had complications due to secondary bacterial infections (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B51" ref-type="bibr">51</xref>).</p><p>During the 2002 outbreak, most SARS patients were treated with broad-spectrum antibiotics as a prophylactic therapy. Contributing factors on antibiotic resistance had not been fully established by the early 2000's; however the use of antibiotics as a precaution in many viral infections and their potential overuse may have contributed to the current antibiotic crisis.</p></sec><sec id="s5"><title>MERS-related Secondary Bacterial Infections and Treatment</title><p>The first cases of the Middle East respiratory syndrome (MERS) CoV epidemic occurred in June 2012 in Saudi Arabia with later outbreaks observed in 2015 and 2018. To date around 2,519 cases have been reported from more than 20 countries with a high fatality rate 34.3% (<italic>n</italic> = 866), the highest among all coronavirus diseases (<xref rid="B52" ref-type="bibr">52</xref>). The infection often starts as a mild viral respiratory illness but can rapidly progress to a fatal viral pneumonia mostly complicated by ARDS (acute respiratory distress syndrome) and ARF (acute renal failure) (<xref rid="B53" ref-type="bibr">53</xref>). Due to the high mortality rate of MERS infections, the impact of the occurrence of bacterial infections remains unclear as death occurs due to hypoxemia and bilateral interstitial infiltrates in most cases, or ARDS. Nosocomial bacterial pneumonia is however common among MERS patients with ventilator support. Therefore, antibiotic therapy was commonly deployed with secondary bacterial infections rarely occurring under this treatment regime (<xref rid="B53" ref-type="bibr">53</xref>&#x02013;<xref rid="B55" ref-type="bibr">55</xref>). Here, we review MERS-related case studies, outlining antibiotic therapies and bacterial infections. A total of 138 MERS-CoV infected patients were reported (<xref rid="B55" ref-type="bibr">55</xref>&#x02013;<xref rid="B59" ref-type="bibr">59</xref>) (<xref ref-type="supplementary-material" rid="SM2">Supplementary File</xref>). The use of prophylactic antibiotic therapy was reported in 4 out of 5 studies. Sixty eight patients were treated with the antibiotics piperacillin-tazobactam, azithromycin, ceftriaxone and trimethoprim- sulfamethoxazole, levofloxacin, imipenem and other broad-spectrum antibiotics (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>, <xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B59" ref-type="bibr">59</xref>). The development of secondary bacterial infection was reported in two studies, with 32 of 82 patients experiencing complications due to bacterial pathogens (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B57" ref-type="bibr">57</xref>). The most common bacteria were MRSA, while others included carbapenem-resistant <italic>Acinetobacter baumannii</italic>, VRE and <italic>S. pneumoniae</italic>. No detailed report was provided about treatment antibiotics and one study reported (patients <italic>n</italic> = 15) complications due to bacterial infections in intensive care units (<xref rid="B55" ref-type="bibr">55</xref>).</p></sec><sec id="s6"><title>Influenza Viruses and Secondary Bacterial Infections</title><p>Influenza viruses are known to cause seasonal flu every year and of the four influenza types, type A and B are known to cause seasonal epidemics (<xref rid="B60" ref-type="bibr">60</xref>). The influenza A (H1N1) outbreak in 2009 had even developed into a global pandemic while causing seasonal flu epidemics each year. In spite of the availability of vaccines, the global death during the flu season was estimated to be between 0.25 and 0.5 million people according to the WHO (<xref rid="B61" ref-type="bibr">61</xref>). Secondary bacterial infections are one of the leading causes for influenza associated deaths (<xref rid="B62" ref-type="bibr">62</xref>). According to the Center for Disease Control and Prevention (CDC), during the 2009 H1N1 influenza pandemic between 29 and 55% of mortalities were due to secondary bacterial infections (<xref rid="B63" ref-type="bibr">63</xref>). The lethal synergism between influenza virus and <italic>Pneumococcus</italic> strains accounts for the majority of diseases as well as mortality during influenza epidemics (<xref rid="B64" ref-type="bibr">64</xref>). Here, we summarize case studies that are related to influenza viruses and secondary bacterial infections (<xref ref-type="supplementary-material" rid="SM2">Supplementary File</xref>). Details on treatment and disease progression of a total of 910 patients that were infected with influenza were reported in eight case studies (<xref rid="B65" ref-type="bibr">65</xref>&#x02013;<xref rid="B72" ref-type="bibr">72</xref>). Five studies reported the deployment of prophylactic antibiotic therapy in 718 of 743 patients (96.6%) (<xref rid="B65" ref-type="bibr">65</xref>&#x02013;<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B71" ref-type="bibr">71</xref>, <xref rid="B72" ref-type="bibr">72</xref>). The most commonly used antibiotics were vancomycin (<italic>n</italic> = 317, 46.2%) and imipenem/meropenem (<italic>n</italic> = 243, 54.7%). Others were azithromycin, ceftriaxone, cephalosporin, piperacillin-tazobactam, linezolid, vancomycin plus cefepime, vancomycin plus meropenem, clarithromycin, levofloxacin and dicloxacillin. In total, 223 patients of 910 (24.5%) developed secondary bacterial infections. The infective agents were <italic>S. pneumoniae</italic>, MRSA, <italic>P. aeruginosa, S. viridians, S. hominis, Enterococci, H. influenza, S. pyogenes, S. mitis, S. agalactiae, Acinetobacter baumannii, E. coli, Chlamydophila pneumoniae</italic>, and <italic>Moraxella catarrhalis</italic>. To treat the infections, one of the studies reported the use of azithromycin, vancomycin, ceftriaxone and cephalosporin (<xref rid="B65" ref-type="bibr">65</xref>). In general, all eight case studies reported the treatment complications due to secondary bacterial infections.</p></sec><sec sec-type="discussion" id="s7"><title>Discussion</title><p>The lack of detailed clinical data regarding secondary bacterial infections following COVID-19, SARS, MERS and influenza is surprising. In addition, precise numbers of clinical cases of COVID-19 or other respiratory virus infections with antibiotic-resistant secondary bacterial infections are not available. As globally mortality rates from antibiotic-resistant bacterial infections are increasing, providing such data of secondary infection is important, almost critical.</p><p>Clinical reports are a valuable source for biomedical scientists for the advancement of treatment; however, in many cases crucial data such as medical compounds, their dosage, and duration of the therapy, is often not reported, similar to details on patient data or the species of e.g., a pathogenic bacterium. Such data are essential for the study of secondary infections in human patients; the scientific community and ultimately the patient will benefit when clinicians and non-clinical disease experts work close together. The information from such collaborative studies can provide a guideline for treatment. At the same time, the lack of knowledge and studies that should be done in the future is evident. Reviewing the available information, it becomes clear that secondary bacterial infections play a critical role in the morbidity and mortality rates of patients initially falling ill with pulmonary viral diseases. Similar to epidemics caused by influenza viruses, during the current SARS-CoV-2 pandemic, antibiotic-resistant bacterial infections are a significant threat to the well-being of hospitalized COVID-19 patients. Nosocomial infections including ventilator-associated infections are often unavoidable and especially so during a pandemic. The use of broad-spectrum antibiotics is often a routine preventative measure and until alternative treatments and to this date unavailable preventive measures are in place at hospitals, secondary infections will remain unavoidable due to the nature of nosocomial and opportunistic pathogens in combination with the rise of multidrug resistance.</p><p>COVID-19 is likely to reappear in populations until a vaccine is deployed, globally. To prepare for recurrent waves of COVID-19 disease and the inevitable next new pandemic, new antibiotics or alternative treatments targeted against secondary bacterial infections are needed. Alternative therapies such as Antimicrobial Peptides or Phage Therapy are being explored and show promise. Most antimicrobial peptides perturb the structure of the bacterial cell envelope while not affecting the eukaryotic cell membrane; eventually creating a leaky lipid bilayer and the collapse of the proton-motif-force, ultimately resulting in bacterial cell death (<xref rid="B73" ref-type="bibr">73</xref>&#x02013;<xref rid="B76" ref-type="bibr">76</xref>). Phage therapy makes use of bacterial viruses (or bacteriophages) that specifically infect bacterial pathogens for viral replication, which leads to the lysis of the host when phage progeny is being released (<xref rid="B77" ref-type="bibr">77</xref>&#x02013;<xref rid="B83" ref-type="bibr">83</xref>). Anti-virulence compounds are substances that do not kill or arrest the growth of a bacterial pathogen, but rather target pathogen-intrinsic components important for the infection process. These include bacterial components such as exo- and endotoxins, i.e., actively secreted toxins (e.g., hemolysins) or cell-inherent structures that are toxic to the patient, such as LPS, and other factors which facilitate adhesion, invasion or colonization, but also the escape of the host's immune system. Anti-virulence compounds have been demonstrated to prevent or reduce the severity of symptoms of acute infections (<xref rid="B84" ref-type="bibr">84</xref>, <xref rid="B85" ref-type="bibr">85</xref>).</p><p>Pulmonary coronaviruses will likely be a clinical challenge for many years to come. Viral pandemics from coronaviruses and emerging pathogens are inevitable in a globalized world with interconnected societies, travel and commerce. We should be well-prepared for the next pandemic, exploring and establishing new avenues to treat bacterial pathogens commonly observed in secondary infections to avert a healthcare crisis due to antibiotic-resistance.</p></sec><sec id="s8"><title>Author Contributions</title><p>PM and SL: initial idea. RN and XH: review and comments. BL and SL: figures. PM, BL, SW, and SL: concept and writing. All authors contributed to the article and approved the submitted version.</p></sec><sec id="s9"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>We thank the Global Challenges Research Fund (the University of Edinburgh) and acknowledge the support by the Zhejiang University Special Scientific Research Fund for COVID-19 prevention and control (2020XGZX037).</p></ack><sec sec-type="supplementary-material" id="s10"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fmed.2020.00420/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fmed.2020.00420/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><label>Supplementary Figure 1</label><caption><p>Overview of case reports of SARS-CoV-2 infection data reviewed in this study, including rate of secondary bacterial infections, antibiotic use and pathogenic bacteria identified.</p></caption><media xlink:href="Image_1.TIF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM2"><label>Supplementary File</label><caption><p>Tables summarizing case reports of patients with pulmonary virus infections and clinical interventions to prevent or cure secondary bacterial infections.</p></caption><media xlink:href="Table_1.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM3"><label>Supplemental Data Sheet 1</label><caption><p>Case reports of patients with secondary bacterial infections.</p></caption><media xlink:href="Data_Sheet_1.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>BT</given-names></name><name><surname>Bryan</surname><given-names>A</given-names></name></person-group>. <article-title>Emerging respiratory Infections: The infectious disease pathology of SARS, MERS, pandemic influenza, and Legionella</article-title>. <source>Semin Diagn Pathol.</source> (<year>2019</year>) <volume>36</volume>:<fpage>152</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1053/j.semdp.2019.04.006</pub-id><?supplied-pmid 31054790?><pub-id pub-id-type="pmid">31054790</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>DE</given-names></name><name><surname>Cleary</surname><given-names>DW</given-names></name><name><surname>Clarke</surname><given-names>SC</given-names></name></person-group>. <article-title>Secondary bacterial infections associated with influenza pandemics</article-title>. <source>Front Microbiol.</source> (<year>2017</year>) <volume>8</volume>:<fpage>1041</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2017.01041</pub-id><?supplied-pmid 28690590?><pub-id pub-id-type="pmid">28690590</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Anthony</surname><given-names>D</given-names></name><name><surname>Selemidis</surname><given-names>S</given-names></name><name><surname>Vlahos</surname><given-names>R</given-names></name><name><surname>Bozinovski</surname><given-names>S</given-names></name></person-group>. <article-title>Resolving viral-induced secondary bacterial infection in COPD: a concise review</article-title>. <source>Front Immunol.</source> (<year>2018</year>) <volume>9</volume>:<fpage>2345</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.02345</pub-id><?supplied-pmid 30459754?><pub-id pub-id-type="pmid">30459754</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallia</surname><given-names>P</given-names></name><name><surname>Footitt</surname><given-names>J</given-names></name><name><surname>Sotero</surname><given-names>R</given-names></name><name><surname>Jepson</surname><given-names>A</given-names></name><name><surname>Contoli</surname><given-names>M</given-names></name><name><surname>Trujillo-Torralbo</surname><given-names>MB</given-names></name><etal/></person-group>. <article-title>Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease</article-title>. <source>Am J Respir Crit Care Med.</source> (<year>2012</year>) <volume>186</volume>:<fpage>1117</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201205-0806OC</pub-id><?supplied-pmid 23024024?><pub-id pub-id-type="pmid">23024024</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chertow</surname><given-names>DS</given-names></name><name><surname>Memoli</surname><given-names>MJ</given-names></name></person-group>. <article-title>Bacterial coinfection in influenza: a grand rounds review</article-title>. <source>JAMA.</source> (<year>2013</year>) <volume>309</volume>:<fpage>275</fpage>&#x02013;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2012.194139</pub-id><?supplied-pmid 23321766?><pub-id pub-id-type="pmid">23321766</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kash</surname><given-names>JC</given-names></name><name><surname>Taubenberger</surname><given-names>JK</given-names></name></person-group>
<article-title>Infectious disease theme issue the role of viral, host, and secondary bacterial factors in influenza pathogenesis</article-title>. <source>Am J Pathol.</source> (<year>2015</year>) <volume>185</volume>:<fpage>1528</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2014.08.030</pub-id><pub-id pub-id-type="pmid">25747532</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacIntyre</surname><given-names>CR</given-names></name><name><surname>Chughtai</surname><given-names>AA</given-names></name><name><surname>Barnes</surname><given-names>M</given-names></name><name><surname>Ridda</surname><given-names>I</given-names></name><name><surname>Seale</surname><given-names>H</given-names></name><name><surname>Toms</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a (H1N1) pdm09</article-title>. <source>BMC Infect Dis.</source> (<year>2018</year>) <volume>18</volume>:<fpage>637</fpage>. <pub-id pub-id-type="doi">10.1186/s12879-018-3548-0</pub-id><?supplied-pmid 30526505?><pub-id pub-id-type="pmid">30526505</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YG</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Reimer</surname><given-names>T</given-names></name><name><surname>Baker</surname><given-names>DP</given-names></name><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Kumar</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Viral infection augments Nod1/2 signaling to potentiate lethality associated with secondary bacterial infections</article-title>. <source>Cell Host Microbe.</source> (<year>2011</year>) <volume>9</volume>:<fpage>496</fpage>&#x02013;<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2011.05.006</pub-id><?supplied-pmid 21669398?><pub-id pub-id-type="pmid">21669398</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamieson</surname><given-names>AM</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Annicelli</surname><given-names>CH</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group>. <article-title>Article influenza virus-induced glucocorticoids compromise innate host defense against a secondary bacterial infection</article-title>. <source>Cell Host Microbe.</source> (<year>2010</year>) <volume>7</volume>:<fpage>103</fpage>&#x02013;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2010.01.010</pub-id><?supplied-pmid 20159617?><pub-id pub-id-type="pmid">20159617</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendaus</surname><given-names>MA</given-names></name><name><surname>Jomha</surname><given-names>FA</given-names></name><name><surname>Alhammadi</surname><given-names>AH</given-names></name></person-group>. <article-title>Virus-induced secondary bacterial infection: a concise review</article-title>. <source>Ther Clin Risk Manag.</source> (<year>2015</year>) <volume>11</volume>:<fpage>1265</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.2147/TCRM.S87789</pub-id><?supplied-pmid 26345407?><pub-id pub-id-type="pmid">26345407</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nyangacha</surname><given-names>RM</given-names></name><name><surname>Odongo</surname><given-names>D</given-names></name><name><surname>Oyieke</surname><given-names>F</given-names></name><name><surname>Ochwoto</surname><given-names>M</given-names></name><name><surname>Korir</surname><given-names>R</given-names></name><name><surname>Ngetich</surname><given-names>RK</given-names></name><etal/></person-group>. <article-title>Secondary bacterial infections and antibiotic resistance among tungiasis patients in Western, Kenya</article-title>. <source>PLoS Neglect Trop D.</source> (<year>2017</year>) <volume>11</volume>:<fpage>e0005901</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pntd.0005901</pub-id><?supplied-pmid 28886013?><pub-id pub-id-type="pmid">28886013</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pittet</surname><given-names>LA</given-names></name><name><surname>Hall-Stoodley</surname><given-names>L</given-names></name><name><surname>Rutkowski</surname><given-names>MR</given-names></name><name><surname>Harmsen</surname><given-names>AG</given-names></name></person-group>. <article-title>Influenza virus infection decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae</article-title>. <source>Am J Resp Cell Mol.</source> (<year>2010</year>) <volume>42</volume>:<fpage>450</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2007-0417OC</pub-id><?supplied-pmid 19520922?><pub-id pub-id-type="pmid">19520922</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>DP</given-names></name></person-group>. <article-title>Bacterial biofilm in upper respiratory tract infections</article-title>. <source>Curr Infect Dis Rep.</source> (<year>2007</year>) <volume>9</volume>:<fpage>186</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1007/s11908-007-0030-3</pub-id><?supplied-pmid 17430699?><pub-id pub-id-type="pmid">17430699</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Handel</surname><given-names>A</given-names></name><name><surname>Longini</surname><given-names>IM</given-names></name><name><surname>Antia</surname><given-names>R</given-names></name></person-group>. <article-title>Intervention strategies for an influenza pandemic taking into account secondary bacterial infections</article-title>. <source>Epidem.</source> (<year>2009</year>) <volume>1</volume>:<fpage>185</fpage>&#x02013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/j.epidem.2009.09.001</pub-id><?supplied-pmid 20161493?><pub-id pub-id-type="pmid">20161493</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullers</surname><given-names>JA</given-names></name></person-group>. <article-title>Preventing and treating secondary bacterial infections with antiviral agents</article-title>. <source>Antivir Ther.</source> (<year>2011</year>) <volume>16</volume>:<fpage>123</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.3851/IMP1730</pub-id><?supplied-pmid 21447860?><pub-id pub-id-type="pmid">21447860</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brook</surname><given-names>I</given-names></name></person-group>. <article-title>Secondary bacterial infections complicating skin lesions</article-title>. <source>J Med Microbiol.</source> (<year>2002</year>) <volume>51</volume>:<fpage>808</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1099/0022-1317-51-10-808</pub-id><?supplied-pmid 12435058?><pub-id pub-id-type="pmid">12435058</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brook</surname><given-names>I</given-names></name></person-group>. <article-title>Microbiology of secondary bacterial infection in scabies lesions</article-title>. <source>J Clin Microbiol.</source> (<year>1995</year>) <volume>33</volume>:<fpage>2139</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1128/JCM.33.8.2139-2140.1995</pub-id><?supplied-pmid 7559963?><pub-id pub-id-type="pmid">7559963</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahar</surname><given-names>PD</given-names></name><name><surname>Wasiak</surname><given-names>J</given-names></name><name><surname>Cleland</surname><given-names>H</given-names></name><name><surname>Paul</surname><given-names>E</given-names></name><name><surname>Gin</surname><given-names>D</given-names></name><name><surname>Watters</surname><given-names>DA</given-names></name><etal/></person-group>. <article-title>Secondary bacterial infection and empirical antibiotic use in toxic epidermal necrolysis patients</article-title>. <source>J Burn Care Res.</source> (<year>2014</year>) <volume>35</volume>:<fpage>518</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1097/BCR.0000000000000062</pub-id><?supplied-pmid 24988228?><pub-id pub-id-type="pmid">24988228</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>McCullers</surname><given-names>JA</given-names></name></person-group>
<article-title>Secondary bacterial infections in influenza virus infection pathogenesis in influenza pathogenesis and control</article-title>. <source>Curr Top Microbiol Immunol</source>. (<year>2014</year>) <volume>385</volume>:<fpage>327</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1007/82_2014_394</pub-id><pub-id pub-id-type="pmid">25027822</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Chordia</surname><given-names>N</given-names></name></person-group>
<article-title>Bacterial resistance against antibiotics</article-title>. In: Arora G, Sajid A, Kalia VC, editors. <source>Drug Resistance in Bacteria, Fungi, Malaria, and Cancer</source>. <publisher-loc>Cham</publisher-loc>: <publisher-name>Springer</publisher-name> (<year>2017</year>). p. <fpage>171</fpage>&#x02013;<lpage>92</lpage>.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="webpage">Available, online at: <ext-link ext-link-type="uri" xlink:href="https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf">https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf</ext-link></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>B</given-names></name><name><surname>Leptihn</surname><given-names>S</given-names></name></person-group>
<article-title>A call for a multidisciplinary future of phage therapy to combat multi-drug resistant bacterial infections</article-title>. <source>Infect Microb Dis.</source> (<year>2020</year>) <volume>2</volume>:<fpage>1</fpage>&#x02013;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1097/IM9.0000000000000018</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>RH</given-names></name><name><surname>Liang</surname><given-names>LR</given-names></name><name><surname>Yang</surname><given-names>CQ</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>TZ</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study</article-title>. <source>Eur Respir J.</source> (<year>2020</year>) <volume>55</volume>:<fpage>2000524</fpage>. <pub-id pub-id-type="doi">10.1183/13993003.00524-2020</pub-id><?supplied-pmid 32269088?><pub-id pub-id-type="pmid">32269088</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Baskota</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of antibiotic agents in children with COVID-19: a rapid review</article-title>. <source>Ann Transl Med.</source> (<year>2020</year>) <volume>8</volume>:<fpage>619</fpage>. <pub-id pub-id-type="doi">10.21037/atm-20-3300</pub-id><?supplied-pmid 32566556?><pub-id pub-id-type="pmid">32566556</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>X</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>F</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study</article-title>. <source>Lancet.</source> (<year>2020</year>) <volume>395</volume>:<fpage>507</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30211-7</pub-id><?supplied-pmid 32007143?><pub-id pub-id-type="pmid">32007143</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Shu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study</article-title>. <source>Lancet Respir Med.</source> (<year>2020</year>) <volume>8</volume>:<fpage>P475</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-2600(20)30079-5</pub-id><?supplied-pmid 32105632?><pub-id pub-id-type="pmid">32105632</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Du</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</article-title>. <source>Lancet.</source> (<year>2020</year>) <volume>395</volume>:<fpage>1054</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30566-3</pub-id><?supplied-pmid 32171076?><pub-id pub-id-type="pmid">32171076</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus&#x02013;infected pneumonia in Wuhan, China</article-title>. <source>JAMA.</source> (<year>2020</year>) <volume>323</volume>:<fpage>1061</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2020.1585</pub-id><?supplied-pmid 32031570?><pub-id pub-id-type="pmid">32031570</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>ML</given-names></name><name><surname>DeBolt</surname><given-names>C</given-names></name><name><surname>Lindquist</surname><given-names>S</given-names></name><name><surname>Lofy</surname><given-names>KH</given-names></name><name><surname>Wiesman</surname><given-names>J</given-names></name><name><surname>Bruce</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>First case of 2019 novel coronavirus in the United States</article-title>. <source>N Engl J Med.</source> (<year>2020</year>) <volume>382</volume>:<fpage>929</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2001191</pub-id><pub-id pub-id-type="pmid">32004427</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>WJ</given-names></name><name><surname>Ni</surname><given-names>ZY</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>WH</given-names></name><name><surname>Ou</surname><given-names>CQ</given-names></name><name><surname>He</surname><given-names>JX</given-names></name><etal/></person-group>
<article-title>Clinical characteristics of coronavirus disease 2019 in China</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>382</volume>:<fpage>1708</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2002032</pub-id><pub-id pub-id-type="pmid">32109013</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruan</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>J</given-names></name></person-group>
<article-title>Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China</article-title>. <source>Intensive Care Med.</source> (<year>2020</year>) <volume>3</volume>:<fpage>1</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1007/s00134-020-06028-z</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China</article-title>. <source>JAMA Intern Med</source>. (<year>2020</year>) <volume>180</volume>:<fpage>1</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2020.0994</pub-id><?supplied-pmid 32167524?><pub-id pub-id-type="pmid">32167524</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>. <source>Lancet.</source> (<year>2020</year>) <volume>395</volume>:<fpage>497</fpage>&#x02013;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><?supplied-pmid 31986264?><pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><etal/></person-group>
<article-title>Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study</article-title>. <source>Clin Infect Dis.</source> (<year>2020</year>) <volume>29</volume>:<fpage>ciaa199</fpage>
<pub-id pub-id-type="doi">10.1093/cid/ciaa199</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gautret</surname><given-names>P</given-names></name><name><surname>Lagier</surname><given-names>JC</given-names></name><name><surname>Parola</surname><given-names>P</given-names></name><name><surname>Meddeb</surname><given-names>L</given-names></name><name><surname>Mailhe</surname><given-names>M</given-names></name><name><surname>Doudier</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title>. <source>Int J Antimicrob Agents.</source> (<year>2020</year>) <fpage>105949</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105949</pub-id>. [Epub ahead of print].<?supplied-pmid 32205204?><pub-id pub-id-type="pmid">32205204</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Easom</surname><given-names>N</given-names></name><name><surname>Moss</surname><given-names>P</given-names></name><name><surname>Barlow</surname><given-names>G</given-names></name><name><surname>Samson</surname><given-names>A</given-names></name><name><surname>Taynton</surname><given-names>T</given-names></name><name><surname>Adams</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>68 Consecutive patients assessed for COVID-19 infection; experience from a UK regional infectious disease unit</article-title>. <source>Influenza Other Respir Viruses</source>. (<year>2020</year>) <volume>14</volume>:<fpage>374</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/irv.12739</pub-id><?supplied-pmid 32223012?><pub-id pub-id-type="pmid">32223012</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study</article-title>. <source>BMJ.</source> (<year>2020</year>) <volume>368</volume>:<fpage>m1295</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.m1295</pub-id><?supplied-pmid 32217556?><pub-id pub-id-type="pmid">32234718</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Wen</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name></person-group>
<article-title>Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China</article-title>. <source>Clin Infect Dis.</source> (<year>2020</year>) <fpage>ciaa272</fpage>
<pub-id pub-id-type="doi">10.1093/cid/ciaa272</pub-id>. [Epub ahead of print].</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Pan</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Han</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Epidemiological and clinical features of 125 hospitalized patients with COVID-19 in Fuyang, Anhui, China</article-title>. <source>Int J Infect Dis</source>. (<year>2020</year>) <volume>95</volume>:<fpage>421</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2020.03.070</pub-id><?supplied-pmid 32289565?><pub-id pub-id-type="pmid">32289565</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>MJ</given-names></name><name><surname>Edwards</surname><given-names>JR</given-names></name><name><surname>Culver</surname><given-names>DH</given-names></name><name><surname>Gaynes</surname><given-names>RP</given-names></name></person-group>. <article-title>Nosocomial infections in medical intensive care units in the United States</article-title>. <source>Crit Care Med.</source> (<year>1999</year>) <volume>27</volume>:<fpage>887</fpage>&#x02013;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1097/00003246-199905000-00020</pub-id><?supplied-pmid 10362409?><pub-id pub-id-type="pmid">10362409</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group>: Available online at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/sars/country/table2004_04_21/en/">http://www.who.int/csr/sars/country/table2004_04_21/en/</ext-link></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="webpage">Available, online at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/don/archive/disease/severe_acute_respiratory_syndrome/en/index.html">http://www.who.int/csr/don/archive/disease/severe_acute_respiratory_syndrome/en/index.html</ext-link></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Korteweg</surname><given-names>C</given-names></name></person-group>
<article-title>Pathology and pathogenesis of severe acute respiratory syndrome</article-title>. <source>Am J Pathol.</source> (<year>2007</year>) <volume>170</volume>:<fpage>1136</fpage>&#x02013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.2353/ajpath.2007.061088</pub-id><pub-id pub-id-type="pmid">17392154</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>VC</given-names></name><name><surname>Chan</surname><given-names>JF</given-names></name><name><surname>To</surname><given-names>KK</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name></person-group>. <article-title>Clinical management and infection control of SARS: lessons learned</article-title>. <source>Antiviral Res.</source> (<year>2013</year>) <volume>100</volume>:<fpage>407</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2013.08.016</pub-id><?supplied-pmid 23994190?><pub-id pub-id-type="pmid">23994190</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>PY</given-names></name><name><surname>Chui</surname><given-names>P</given-names></name><name><surname>Ling</surname><given-names>AE</given-names></name><name><surname>Franks</surname><given-names>TJ</given-names></name><name><surname>Tai</surname><given-names>DY</given-names></name><name><surname>Leo</surname><given-names>YS</given-names></name><etal/></person-group>. <article-title>Analysis of deaths during the severe acute respiratory syndrome (SARS) epidemic in Singapore: challenges in determining a SARS diagnosis</article-title>. <source>Arch Pathol Lab Med.</source> (<year>2004</year>) <volume>128</volume>:<fpage>195</fpage>&#x02013;<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1043/1543-2165(2004)128&#x0003c;195:AODDTS&#x0003e;2.0.CO;2</pub-id><?supplied-pmid 14736283?><pub-id pub-id-type="pmid">14736283</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>So</surname><given-names>LK</given-names></name><name><surname>Lau</surname><given-names>AC</given-names></name><name><surname>Yam</surname><given-names>LY</given-names></name><name><surname>Cheung</surname><given-names>TM</given-names></name><name><surname>Poon</surname><given-names>E</given-names></name><name><surname>Yung</surname><given-names>RW</given-names></name><etal/></person-group>. <article-title>Development of a standard treatment protocol for severe acute respiratory syndrome</article-title>. <source>Lancet.</source> (<year>2003</year>) <volume>361</volume>:<fpage>1615</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(03)13265-5</pub-id><?supplied-pmid 12747883?><pub-id pub-id-type="pmid">12747883</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Hui</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>P</given-names></name><name><surname>Cameron</surname><given-names>P</given-names></name><name><surname>Joynt</surname><given-names>GM</given-names></name><etal/></person-group>. <article-title>A major outbreak of severe acute respiratory syndrome in Hong Kong</article-title>. <source>N Engl J Med.</source> (<year>2003</year>) <volume>348</volume>:<fpage>1986</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa030685</pub-id><?supplied-pmid 12682352?><pub-id pub-id-type="pmid">12682352</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsang</surname><given-names>KW</given-names></name><name><surname>Ho</surname><given-names>PL</given-names></name><name><surname>Ooi</surname><given-names>GC</given-names></name><name><surname>Yee</surname><given-names>WK</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Chan-Yeung</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>A cluster of cases of severe acute respiratory syndrome in Hong Kong</article-title>. <source>N Engl J Med.</source> (<year>2003</year>) <volume>348</volume>:<fpage>1977</fpage>&#x02013;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa030666</pub-id><?supplied-pmid 12671062?><pub-id pub-id-type="pmid">12671062</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>JS</given-names></name><name><surname>Chu</surname><given-names>CM</given-names></name><name><surname>Cheng</surname><given-names>VC</given-names></name><name><surname>Chan</surname><given-names>KS</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name><etal/></person-group>. <article-title>Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study</article-title>. <source>Lancet.</source> (<year>2003</year>) <volume>361</volume>:<fpage>1767</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(03)13412-5</pub-id><?supplied-pmid 12781535?><pub-id pub-id-type="pmid">12781535</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>K</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China</article-title>. <source>J Med Microbiol.</source> (<year>2003</year>) <volume>52</volume>:<fpage>715</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1099/jmm.0.05320-0</pub-id><?supplied-pmid 12867568?><pub-id pub-id-type="pmid">12867568</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>JT</given-names></name><name><surname>Sheng</surname><given-names>WH</given-names></name><name><surname>Fang</surname><given-names>CT</given-names></name><name><surname>Chen</surname><given-names>YC</given-names></name><name><surname>Wang</surname><given-names>JL</given-names></name><name><surname>Yu</surname><given-names>CJ</given-names></name><etal/></person-group>. <article-title>Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients</article-title>. <source>Emerg Infect Dis.</source> (<year>2004</year>) <volume>10</volume>:<fpage>818</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.3201/eid1005.030640</pub-id><?supplied-pmid 15200814?><pub-id pub-id-type="pmid">15200814</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="webpage">Available, online at: <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/">https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/</ext-link></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cunha</surname><given-names>CB</given-names></name><name><surname>Opal</surname><given-names>SM</given-names></name></person-group>
<article-title>Middle east respiratory syndrome (MERS) A new zoonotic viral pneumonia</article-title>. <source>Virulence.</source> (<year>2014</year>) <volume>5</volume>:<fpage>650</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.4161/viru.32077</pub-id><pub-id pub-id-type="pmid">25089913</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Memish</surname><given-names>ZA</given-names></name><name><surname>Cotten</surname><given-names>M</given-names></name><name><surname>Watson</surname><given-names>SJ</given-names></name><name><surname>Kellam</surname><given-names>P</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Alhakeem</surname><given-names>RF</given-names></name><etal/></person-group>. <article-title>Community case clusters of middle east respiratory syndrome coronavirus in Hafr Al-Batin, Kingdom of Saudi Arabia: a descriptive genomic study</article-title>. <source>Int J Infect Dis.</source> (<year>2014</year>) <volume>23</volume>:<fpage>63</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2014.03.1372</pub-id><?supplied-pmid 24699184?><pub-id pub-id-type="pmid">24699184</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>YM</given-names></name><name><surname>Arifi</surname><given-names>AA</given-names></name><name><surname>Balkhy</surname><given-names>HH</given-names></name><name><surname>Najm</surname><given-names>H</given-names></name><name><surname>Aldawood</surname><given-names>AS</given-names></name><name><surname>Ghabashi</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Clinical course and outcomes of critically ill patients with middle east respiratory syndrome coronavirus infection</article-title>. <source>Ann Intern Med.</source> (<year>2014</year>) <volume>160</volume>:<fpage>389</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.7326/M13-2486</pub-id><?supplied-pmid 24474051?><pub-id pub-id-type="pmid">24474051</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Tawfiq</surname><given-names>JA</given-names></name><name><surname>Momattin</surname><given-names>H</given-names></name><name><surname>Dib</surname><given-names>J</given-names></name><name><surname>Memish</surname><given-names>ZA</given-names></name></person-group>. <article-title>Ribavirin and interferon therapy in patients infected with the middle east respiratory syndrome coronavirus: an observational study</article-title>. <source>Int J Infect Dis.</source> (<year>2014</year>) <volume>20</volume>:<fpage>42</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2013.12.003</pub-id><?supplied-pmid 24406736?><pub-id pub-id-type="pmid">24406736</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saad</surname><given-names>M</given-names></name><name><surname>Omrani</surname><given-names>AS</given-names></name><name><surname>Baig</surname><given-names>K</given-names></name><name><surname>Bahloul</surname><given-names>A</given-names></name><name><surname>Elzein</surname><given-names>F</given-names></name><name><surname>Matin</surname><given-names>MA</given-names></name><etal/></person-group>. <article-title>Clinical aspects and outcomes of 70 patients with middle east respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia</article-title>. <source>Int J Infect Dis.</source> (<year>2014</year>) <volume>29</volume>:<fpage>301</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2014.09.003</pub-id><?supplied-pmid 25303830?><pub-id pub-id-type="pmid">25303830</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Assiri</surname><given-names>A</given-names></name><name><surname>Al-Tawfiq</surname><given-names>JA</given-names></name><name><surname>Al-Rabeeah</surname><given-names>AA</given-names></name><name><surname>Al-Rabiah</surname><given-names>FA</given-names></name><name><surname>Al-Hajjar</surname><given-names>S</given-names></name><name><surname>Al-Barrak</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Epidemiological, demographic, and clinical characteristics of 47 cases of middle east respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study</article-title>. <source>Lancet Infect Dis.</source> (<year>2013</year>) <volume>13</volume>:<fpage>752</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(13)70204-4</pub-id><?supplied-pmid 23891402?><pub-id pub-id-type="pmid">23891402</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Memish</surname><given-names>ZA</given-names></name><name><surname>Zumla</surname><given-names>AI</given-names></name><name><surname>Al-Hakeem</surname><given-names>RF</given-names></name><name><surname>Al-Rabeeah</surname><given-names>AA</given-names></name><name><surname>Stephens</surname><given-names>GM</given-names></name></person-group>. <article-title>Family cluster of middle east respiratory syndrome coronavirus infections</article-title>. <source>N Engl J Med.</source> (<year>2013</year>) <volume>368</volume>:<fpage>2487</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1303729</pub-id><?supplied-pmid 23718156?><pub-id pub-id-type="pmid">23718156</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="webpage">Available, online at: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/about/viruses/types.htm">https://www.cdc.gov/flu/about/viruses/types.htm</ext-link></mixed-citation></ref><ref id="B61"><label>61.</label><element-citation publication-type="webpage"><ext-link ext-link-type="uri" xlink:href="https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/">https://www.who.int/influenza/surveillance_monitoring/updates/latest_update_GIP_surveillance/en/</ext-link></element-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullers</surname><given-names>JA</given-names></name></person-group>. <article-title>Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza</article-title>. <source>J Infect Dis.</source> (<year>2004</year>) <volume>190</volume>:<fpage>519</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1086/421525</pub-id><?supplied-pmid 15243927?><pub-id pub-id-type="pmid">15243927</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Center for Disease Control and Prevention (CDC)</collab></person-group> (<year>2012</year>) Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/flu/spotlights/pandemic-global-estimates.htm">https://www.cdc.gov/flu/spotlights/pandemic-global-estimates.htm</ext-link> (accessed May 10, 2020).</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullers</surname><given-names>JA</given-names></name><name><surname>Bartmess</surname><given-names>KC</given-names></name></person-group>. <article-title>Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae</article-title>. <source>J Infect Dis.</source> (<year>2003</year>) <volume>187</volume>:<fpage>1000</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1086/368163</pub-id><?supplied-pmid 12660947?><pub-id pub-id-type="pmid">12660947</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chitnis</surname><given-names>AS</given-names></name><name><surname>Truelove</surname><given-names>SA</given-names></name><name><surname>Druckenmiller</surname><given-names>JK</given-names></name><name><surname>Heffernan</surname><given-names>RT</given-names></name><name><surname>Davis</surname><given-names>JP</given-names></name></person-group>. <article-title>Epidemiologic and clinical features among patients hospitalized in Wisconsin with 2009. H1N1 influenza A virus infections, April to August. 2009</article-title>. <source>Wisconsin Med J</source>. (<year>2010</year>) <volume>109</volume>:<fpage>201</fpage>&#x02013;<lpage>8</lpage>.<?supplied-pmid 20945721?><pub-id pub-id-type="pmid">20945721</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusznierz</surname><given-names>G</given-names></name><name><surname>Uboldi</surname><given-names>A</given-names></name><name><surname>Sosa</surname><given-names>G</given-names></name><name><surname>Torales</surname><given-names>S</given-names></name><name><surname>Colombo</surname><given-names>J</given-names></name><name><surname>Moyano</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Clinical features of the hospitalized patients with 2009 pandemic influenza A (H1N1) in Santa Fe, Argentina</article-title>. <source>Influenza Other Respir Viruses.</source> (<year>2013</year>) <volume>7</volume>:<fpage>410</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1750-2659.2012.00405.x</pub-id><?supplied-pmid 22817648?><pub-id pub-id-type="pmid">22817648</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crotty</surname><given-names>MP</given-names></name><name><surname>Meyers</surname><given-names>S</given-names></name><name><surname>Hampton</surname><given-names>N</given-names></name><name><surname>Bledsoe</surname><given-names>S</given-names></name><name><surname>Ritchie</surname><given-names>DJ</given-names></name><name><surname>Buller</surname><given-names>RS</given-names></name><etal/></person-group>. <article-title>Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: an opportunity for stewardship</article-title>. <source>Critical Care.</source> (<year>2015</year>) <volume>19</volume>:<fpage>404</fpage>. <pub-id pub-id-type="doi">10.1186/s13054-015-1120-5</pub-id><?supplied-pmid 26577540?><pub-id pub-id-type="pmid">26577540</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abelenda-Alonso</surname><given-names>G</given-names></name><name><surname>Rombauts</surname><given-names>A</given-names></name><name><surname>Gudiol</surname><given-names>C</given-names></name><name><surname>Meije</surname><given-names>Y</given-names></name><name><surname>Ortega</surname><given-names>L</given-names></name><name><surname>Clemente</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Influenza and bacterial coinfection in adults with community-acquired pneumonia admitted to conventional wards: risk factors, clinical features, and outcomes</article-title>. <source>Open Forum Infect Dis.</source> (<year>2020</year>) <volume>7</volume>:<fpage>ofaa066</fpage>. <pub-id pub-id-type="doi">10.1093/ofid/ofaa066</pub-id><?supplied-pmid 32206675?><pub-id pub-id-type="pmid">32206675</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hughes</surname><given-names>JM</given-names></name><name><surname>Wilson</surname><given-names>ME</given-names></name><name><surname>Hughes</surname><given-names>JM</given-names></name><name><surname>Wilson</surname><given-names>ME</given-names></name><name><surname>Lee</surname><given-names>EH</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Fatalities associated with the 2009. H1N1 influenza A virus in New York city</article-title>. <source>Clin Infect Dis.</source> (<year>2010</year>) <volume>50</volume>:<fpage>1498</fpage>&#x02013;<lpage>504</lpage>. <pub-id pub-id-type="doi">10.1086/652446</pub-id><pub-id pub-id-type="pmid">20420514</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shieh</surname><given-names>WJ</given-names></name><name><surname>Blau</surname><given-names>DM</given-names></name><name><surname>Denison</surname><given-names>AM</given-names></name><name><surname>DeLeon-Carnes</surname><given-names>M</given-names></name><name><surname>Adem</surname><given-names>P</given-names></name><name><surname>Bhatnagar</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States</article-title>. <source>Am J Pathol</source>. (<year>2010</year>) <volume>177</volume>:<fpage>166</fpage>&#x02013;<lpage>75</lpage>.<?supplied-pmid 20508031?><pub-id pub-id-type="pmid">20508031</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>N</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Katano</surname><given-names>H</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name><name><surname>Kumasaka</surname><given-names>T</given-names></name><name><surname>Hata</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Histopathological and immunohistochemical findings of 20 autopsy cases with (2009). H1N1 virus infection</article-title>. <source>Modern Pathol.</source> (<year>2012</year>) <volume>25</volume>:<fpage>1</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/modpathol.2011.180</pub-id><?supplied-pmid 21874012?><pub-id pub-id-type="pmid">21874012</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Padilla</surname><given-names>R</given-names></name><name><surname>De La Rosa-Zamboni</surname><given-names>D</given-names></name><name><surname>Ponce de Leon</surname><given-names>S</given-names></name><name><surname>Hernandez</surname><given-names>M</given-names></name><name><surname>Qui&#x000f1;ones-Falconi</surname><given-names>F</given-names></name><name><surname>Bautista</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico</article-title>. <source>N Engl J Med.</source> (<year>2009</year>) <volume>361</volume>:<fpage>680</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0904252</pub-id><?supplied-pmid 19564631?><pub-id pub-id-type="pmid">19564631</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazzaro</surname><given-names>BP</given-names></name><name><surname>Zasloff</surname><given-names>M</given-names></name><name><surname>Rolff</surname><given-names>J</given-names></name></person-group>. <article-title>Antimicrobial peptides: application informed by evolution</article-title>. <source>Science</source>. (<year>2020</year>) <volume>368</volume>:<fpage>eaau5480</fpage>. <pub-id pub-id-type="doi">10.1126/science.aau5480</pub-id><?supplied-pmid 32355003?><pub-id pub-id-type="pmid">32355003</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brogden</surname><given-names>KA</given-names></name></person-group>
<article-title>Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?</article-title>
<source>Nat Rev Microbiol.</source> (<year>2005</year>) <volume>3</volume>:<fpage>238</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro1098</pub-id><pub-id pub-id-type="pmid">15703760</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leptihn</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Frecer</surname><given-names>V</given-names></name><name><surname>Ho</surname><given-names>B</given-names></name><name><surname>Ding</surname><given-names>JL</given-names></name><name><surname>Wohland</surname><given-names>T</given-names></name></person-group>. <article-title>One step at a time: action mechanism of Sushi 1 antimicrobial peptide and derived molecules</article-title>. <source>Virulence.</source> (<year>2010</year>) <volume>1</volume>:<fpage>42</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.4161/viru.1.1.10229</pub-id><?supplied-pmid 21178412?><pub-id pub-id-type="pmid">21178412</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leptihn</surname><given-names>S</given-names></name><name><surname>Har</surname><given-names>JY</given-names></name><name><surname>Wohland</surname><given-names>T</given-names></name><name><surname>Ding</surname><given-names>JL</given-names></name></person-group>. <article-title>Correlation of charge, hydrophobicity, and structure with antimicrobial activity of S1 and MIRIAM peptides</article-title>. <source>Biochemistry.</source> (<year>2010</year>) <volume>49</volume>:<fpage>9161</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1021/bi1011578</pub-id><?supplied-pmid 20873868?><pub-id pub-id-type="pmid">20873868</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kortright</surname><given-names>KE</given-names></name><name><surname>Chan</surname><given-names>BK</given-names></name><name><surname>Koff</surname><given-names>JL</given-names></name><name><surname>Turner</surname><given-names>PE</given-names></name></person-group>. <article-title>Phage therapy: a renewed approach to combat antibiotic-resistant bacteria</article-title>. <source>Cell Host Microbe.</source> (<year>2019</year>) <volume>25</volume>:<fpage>219</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2019.01.014</pub-id><?supplied-pmid 30763536?><pub-id pub-id-type="pmid">30763536</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manohar</surname><given-names>P</given-names></name><name><surname>Stalsby Lundborg</surname><given-names>C</given-names></name><name><surname>Tamhankar</surname><given-names>AJ</given-names></name><name><surname>Nachimuthu</surname><given-names>R</given-names></name></person-group>. <article-title>Therapeutic characterization and efficacy of bacteriophage cocktails infecting <italic>Escherichia coli</italic>, klebsiella pneumoniae and enterobacter species</article-title>. <source>Front Microbiol.</source> (<year>2019</year>) <volume>10</volume>:<fpage>574</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2019.00574</pub-id><?supplied-pmid 30949158?><pub-id pub-id-type="pmid">30949158</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altamirano</surname><given-names>FL</given-names></name><name><surname>Barr</surname><given-names>JJ</given-names></name></person-group>
<article-title>Phage therapy in the postantibiotic era</article-title>. <source>Clin Microbiol Rev.</source> (<year>2019</year>) <volume>32</volume>:<fpage>e00066</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00066-18</pub-id><pub-id pub-id-type="pmid">30651225</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abedon</surname><given-names>ST</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>P</given-names></name><name><surname>Mullany</surname><given-names>P</given-names></name><name><surname>Aminov</surname><given-names>R</given-names></name></person-group>. <article-title>Phage therapy: past, present and future</article-title>. <source>Front Microbiol.</source> (<year>2017</year>) <volume>8</volume>:<fpage>981</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2017.00981</pub-id><?supplied-pmid 28663740?><pub-id pub-id-type="pmid">28663740</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cisek</surname><given-names>AA</given-names></name><name><surname>Dabrowska</surname><given-names>I</given-names></name><name><surname>Gregorczyk</surname><given-names>KP</given-names></name><name><surname>Wyzewski</surname><given-names>Z</given-names></name></person-group>. <article-title>Phage therapy in bacterial infections treatment: one hundred years after the discovery of bacteriophages</article-title>. <source>Curr Microbiol.</source> (<year>2017</year>) <volume>74</volume>:<fpage>277</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1007/s00284-016-1166-x</pub-id><?supplied-pmid 27896482?><pub-id pub-id-type="pmid">27896482</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manohar</surname><given-names>P</given-names></name><name><surname>Tamhankar</surname><given-names>AJ</given-names></name><name><surname>Leptihn</surname><given-names>S</given-names></name><name><surname>Nachimuthu</surname><given-names>R</given-names></name></person-group>
<article-title>Pharmacological and immunological aspects of phage therapy</article-title>. <source>Infect Microb Dis.</source> (<year>2019</year>) <volume>1</volume>:<fpage>34</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1097/IM9.0000000000000013</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manohar</surname><given-names>P</given-names></name><name><surname>Loh</surname><given-names>B</given-names></name><name><surname>Athira</surname><given-names>S</given-names></name><name><surname>Nachimuthu</surname><given-names>R</given-names></name><name><surname>Hua</surname><given-names>X</given-names></name><name><surname>Welburn</surname><given-names>SC</given-names></name><etal/></person-group>. <article-title>Secondary bacterial infections during pulmonary viral disease: phage therapeutics as alternatives to antibiotics?</article-title>
<source>Front Microbiol.</source> (<year>2020</year>) <volume>11</volume>:<fpage>1434</fpage>. <pub-id pub-id-type="doi">10.3389/fmicb.2020.01434</pub-id><?supplied-pmid 32733404?><pub-id pub-id-type="pmid">32733404</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>BK</given-names></name><name><surname>Abramovitch</surname><given-names>RB</given-names></name></person-group>. <article-title>Small molecules that sabotage bacterial virulence</article-title>. <source>Trends Pharmacol Sci.</source> (<year>2017</year>) <volume>38</volume>:<fpage>339</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2017.01.004</pub-id><?supplied-pmid 28209403?><pub-id pub-id-type="pmid">28209403</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Starkey</surname><given-names>M</given-names></name><name><surname>Lepine</surname><given-names>F</given-names></name><name><surname>Maura</surname><given-names>D</given-names></name><name><surname>Bandyopadhaya</surname><given-names>A</given-names></name><name><surname>Lesic</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Identification of anti-virulence compounds that disrupt quorum-sensing regulated acute and persistent pathogenicity</article-title>. <source>PLoS Pathog.</source> (<year>2014</year>) <volume>10</volume>:<fpage>e1004321</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1004321</pub-id><?supplied-pmid 25144274?><pub-id pub-id-type="pmid">25144274</pub-id></mixed-citation></ref></ref-list></back></article>